Developer docs
API playgroundTry for free, no card

Search company profiles

Bioxyne

Full company profile

uuid0037th9

Namestring
Bioxyne
Legal namestring
Bioxyne Ltd
Websiteurl
bioxyne.com
Company typeenum
Public
Founded yearint
2010
Descriptiontext

Bioxyne Ltd (ASX: BXN) is an Australian publicly-listed pharmaceutical manufacturing and distribution group operating through its wholly-owned subsidiary Breathe Life Sciences (BLS) and the BLS Pharma parent brand. The group holds a TGA GMP-licensed manufacturing facility in Brisbane and is the first and only entity in Australia to have received a GMP manufacturing license for MDMA and Psilocybin (February 2024). Bioxyne's core business is contract drug manufacturing, sponsorship, import/export, and wholesale distribution of investigational and psychotropic medicines, including medicinal cannabis, MDMA, and psilocybin products, with manufacturing capabilities spanning Schedule 3, 4, and 8 medicines. Its clients include licensed clinics, pharmacies, wholesale distributors, cultivators, active pharmaceutical ingredient manufacturers, and pharmaceutical brand sponsors, served across Australasia, the UK, Germany, the EU, Japan, and the USA.

Bioxyne generates revenue through multiple streams: contract pharmaceutical manufacturing under GMP, wholesale distribution of controlled substances (via BLS Wholesalers), exclusive supply agreements with international partners (such as the AU$50 million ADREXpharma deal for the German market and a manufacturing partnership with Aurora Cannabis covering sublingual oils and vape products), and direct-to-consumer sales of own-brand health products under the Dr Watson® and PCC® brands via e-commerce and Amazon. The company reports 3,000,000+ medicines manufactured annually across 200+ brands distributed to 10+ countries, with Breathe Life Sciences having scaled from AU$8 million annual turnover to AU$8 million per month in revenue.

The group is structured into three primary commercial entities: Breathe Life Sciences (pharmaceutical manufacturing and wholesale), BLS Wholesalers (Australian licensed importer/manufacturer/wholesaler), and Dr Watson® (consumer health brand covering CBD, NADs, and functional mushrooms). Leadership is anchored by founder and managing director Samuel Watson. The strategic positioning is a regulatory-first contract manufacturer leveraging Australia's unique TGA pathway for psychedelic medicines to serve both domestic special access prescribers and international pharmaceutical sponsors, with management's stated goal of becoming a billion-dollar company within five years.

Short descriptiontext

Bioxyne is an Australian publicly-listed pharmaceutical manufacturer and distributor operating through Breathe Life Sciences, holding Australia's first GMP license for MDMA and psilocybin. It contract-manufactures and distributes medicinal cannabis, MDMA, and psilocybin products to licensed clinics, pharmacies, and international pharmaceutical partners across 10+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSydney, Australia
HQ citystring
Sydney
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
GMP pharmaceutical manufacturing, medicinal cannabis manufacturing, investigational medicines distribution, contract drug manufacturing, consumer health supplements
Industry4 codes
PRIMARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAIAJAH
Biologics & Biosimilars Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYCRAOAHAD
Specialty Pharmacy & Biologics Distribution
NAICS code4 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Biological Product (except Diagnostic) Manufacturing325414
  • Medicinal and Botanical Manufacturing325411
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Biological Products, (No Disgnostic Substances)2836
Product category
Contract Pharmaceutical Manufacturing
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Contract Pharmaceutical Manufacturing (GMP)
TypeProfessional Services
Description

Contract drug manufacturing services for clients including licensed clinics, pharmacies, wholesale distributors, cultivators, active pharmaceutical ingredient manufacturers, and pharmaceutical brand sponsors. Services include wholesale and distribution of medicinal cannabis, MDMA, and psilocybin products.

blspharma.com
2Medicinal Cannabis Supply Agreements
TypeTransaction Fee
Description

Supply deals for medicinal cannabis products including the AU$50 million two-year supply agreement with ADREXpharma for the German market.

moomoo.com
3Own-Brand Products (Dr Watson, PCC)
TypeOne Time License
Description

Direct-to-consumer and retail distribution of own-brand prescription medicines and health products including Dr Watson CBD products, NADs, and food grade mushrooms.

blspharma.com
4Wholesale Distribution Services
TypeTransaction Fee
Description

Wholesale distribution services for medicinal cannabis and controlled substances in Australia, Europe, UK, Japan, and USA through BLS Wholesalers and Breathe Life Sciences.

blspharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Dr Watson
Description

Internationally trademarked direct-to-consumer brand featuring supplements, nootropics, functional mushrooms, and skincare. Approved by Amazon for CBD products. Operates in UK, EU, Japan, and USA.

blspharma.com
+1 more record
Core offering1 text field

Bioxyne, through its BLS Pharma and Breathe Life Sciences subsidiaries, is a contract drug manufacturer, sponsor, importer, exporter, and wholesale distributor of investigational medicines including medicinal cannabis, MDMA, and psilocybin products. It also produces and distributes own-brand consumer health products (Dr Watson, PCC) such as CBD, nootropics, functional mushrooms, NADs, and skincare via direct e-commerce and Amazon.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Scaled from $8M annual turnover to $8M monthly revenue
+2 more records
Product overview1 text field

BLS Pharma/Bioxyne operates a multi-brand pharmaceutical and life sciences platform consisting of the BLS (Breathe Life Sciences) manufacturing and wholesale subsidiary, Dr Watson® direct-to-consumer brand, and BLS Wholesalers. The core BLS subsidiary provides GMP-certified contract pharmaceutical manufacturing for cannabis, MDMA, and psilocybin products across Australia, Europe, and the UK. The Dr Watson® brand serves consumers with CBD supplements, nootropics, functional mushrooms, and skincare, while the PCC® brand represents legacy consumer health products. The group offers end-to-end services including R&D, manufacturing, quality control, import/export, and international distribution of investigational medicines and consumer health products.

Product and service4 records
1GMP Contract Pharmaceutical Manufacturing
CategoryContract Pharmaceutical Manufacturing
Description

Contract drug manufacturing, sponsor, import, export, and wholesale distribution services for investigational and psychotropic medicines (cannabis, MDMA, psilocybin) delivered under TGA GMP licence for licensed clinics, pharmacies, wholesale distributors, cultivators, API manufacturers, and pharmaceutical brand sponsors.

2GMP Psilocybin Capsules
CategoryInvestigational Pharmaceutical Product
Description

GMP-manufactured psilocybin capsules commercialised for the Australian market for investigational treatment of mental health disorders.

3BLS Wholesalers Distribution Services
CategoryPharmaceutical Wholesale Distribution
Description

Licensed wholesale distribution of Schedule 3, 4, and 8 medicines (medicinal cannabis and controlled substances) to pharmacies, manufacturers, and patients nationwide in Australia.

4Dr Watson Consumer Health Brand
CategoryConsumer Health & Wellness Products
Description

Internationally trademarked direct-to-consumer brand featuring CBD products, NADs, functional mushrooms, nootropics, and skincare, distributed via direct e-commerce and Amazon in UK, EU, Japan, USA, and Australasia.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-01
Description

AU$50 million exclusive medicinal cannabis supply agreement with German pharmaceutical company ADREXpharma. Two-year contract facilitating Bioxyne's entry into the German medicinal cannabis market, with AU$25 million minimum guaranteed in first year. Deal significantly boosts European revenue visibility.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Manufacturing agreement with global cannabis leader Aurora Cannabis Inc. covering GMP-certified medicinal cannabis oils for Australian market with first deliveries completed. Expansion planned into GMP-manufactured cannabis vapes for Australia, UK, and Germany. Deal provides third-party validation of Bioxyne's GMP manufacturing capabilities and entry into Aurora's global supply chain. Products include over 5,000 sublingual oil products and 20,000 vape units.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

NASDAQ/TSX-listed large global cannabis operator. Functions both as a Bioxyne customer (manufacturing agreement) and a broader incumbent shaping the global medicinal cannabis supply chain that Bioxyne contracts into.

TypeDirect peer
Description

TSX-listed (LABS) pure-play cannabis contract manufacturer with GMP-certified facilities. Highly analogous business model to BLS - contract GMP manufacturing and wholesale of cannabinoid APIs/products - making it one of the closest comparable contract manufacturers globally.

TypeDirect peer
Description

ASX-listed Australian medicinal cannabis cultivator and manufacturer with TGA GMP-licensed facilities. Closest direct Australian comparison: same regulatory licensing environment, same customer base of clinics/pharmacies, overlapping Schedule 4/8 medicine focus.

TypeDirect peer
Description

NASDAQ-listed (CLVR) Colombian-based GMP-certified cannabis cultivator and B2B manufacturer. Comparable contract-manufacturing and white-label distribution model serving international cannabis brands, similar to BLS's relationship with Aurora Cannabis.

TypeDirect peer
Description

ASX-listed (AGH) Australian medicinal cannabis company covering cultivation, manufacturing, wholesale distribution, and education to clinicians. Operates in the same TGA-licensed ecosystem and targets identical pharmacy/clinic customers.

TypeDirect peer
Description

ASX-listed (VIT, formerly Cronos Australia) Australian medicinal cannabis distribution and consumer health company. Direct peer operating in identical pharmacy/clinic distribution channels and competing for the same prescriber relationships across Australia.

7Mind Medicine (MindMed) Inc.
TypeDirect peer
Description

NASDAQ/NEO-listed (MNMD) psychedelic medicine developer focused on MDMA, LSD and psilocybin for mental health. Direct peer to Bioxyne's GMP MDMA/psilocybin manufacturing capability on the supply side of the same psychedelic ecosystem.

TypeDirect peer
Description

ASX-listed (BOD) Australian medicinal cannabis and CBD consumer health company. Direct competitor in Australian pharmacy/clinic distribution and overlapping D2C CBD product lines with Bioxyne's Dr Watson brand.

TypeRegional player
Description

LSE-listed (OCTP) UK-based cannabinoid drug development company. Operates in the same UK medicinal cannabis regulation environment as Bioxyne's Breathe Life Sciences UK entity and pursues overlapping novel cannabinoid therapeutics for pain indications.

TypeDirect peer
Description

NASDAQ-listed (CMPS) developer of psilocybin therapy for treatment-resistant depression. A direct peer in the same psychedelic medicine category Bioxyne manufactures for, sharing the mental-health indication focus and regulatory pathway timeline.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bioxyne

Contract Pharmaceutical Manufacturingbioxyne.com

Bioxyne is an Australian publicly-listed pharmaceutical manufacturer and distributor operating through Breathe Life Sciences, holding Australia's first GMP license for MDMA and psilocybin. It contract-manufactures and distributes medicinal cannabis, MDMA, and psilocybin products to licensed clinics, pharmacies, and international pharmaceutical partners across 10+ countries.

What Bioxyne does

Bioxyne Ltd (ASX: BXN) is an Australian publicly-listed pharmaceutical manufacturing and distribution group operating through its wholly-owned subsidiary Breathe Life Sciences (BLS) and the BLS Pharma parent brand. The group holds a TGA GMP-licensed manufacturing facility in Brisbane and is the first and only entity in Australia to have received a GMP manufacturing license for MDMA and Psilocybin (February 2024). Bioxyne's core business is contract drug manufacturing, sponsorship, import/export, and wholesale distribution of investigational and psychotropic medicines, including medicinal cannabis, MDMA, and psilocybin products, with manufacturing capabilities spanning Schedule 3, 4, and 8 medicines. Its clients include licensed clinics, pharmacies, wholesale distributors, cultivators, active pharmaceutical ingredient manufacturers, and pharmaceutical brand sponsors, served across Australasia, the UK, Germany, the EU, Japan, and the USA.

Bioxyne generates revenue through multiple streams: contract pharmaceutical manufacturing under GMP, wholesale distribution of controlled substances (via BLS Wholesalers), exclusive supply agreements with international partners (such as the AU$50 million ADREXpharma deal for the German market and a manufacturing partnership with Aurora Cannabis covering sublingual oils and vape products), and direct-to-consumer sales of own-brand health products under the Dr Watson® and PCC® brands via e-commerce and Amazon. The company reports 3,000,000+ medicines manufactured annually across 200+ brands distributed to 10+ countries, with Breathe Life Sciences having scaled from AU$8 million annual turnover to AU$8 million per month in revenue.

The group is structured into three primary commercial entities: Breathe Life Sciences (pharmaceutical manufacturing and wholesale), BLS Wholesalers (Australian licensed importer/manufacturer/wholesaler), and Dr Watson® (consumer health brand covering CBD, NADs, and functional mushrooms). Leadership is anchored by founder and managing director Samuel Watson. The strategic positioning is a regulatory-first contract manufacturer leveraging Australia's unique TGA pathway for psychedelic medicines to serve both domestic special access prescribers and international pharmaceutical sponsors, with management's stated goal of becoming a billion-dollar company within five years.

Bioxyne firmographics

Firmographics
Name
Bioxyne
Legal name
Bioxyne Ltd
Website
https://bioxyne.com
Company type
Public
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Short description
Bioxyne is an Australian publicly-listed pharmaceutical manufacturer and distributor operating through Breathe Life Sciences, holding Australia's first GMP license for MDMA and psilocybin. It contract-manufactures and distributes medicinal cannabis, MDMA, and psilocybin products to licensed clinics, pharmacies, and international pharmaceutical partners across 10+ countries.
Ownership category
akta.pro rank

Bioxyne industry classification

Industry
Product category
Contract Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAIAJAH
Biologics & Biosimilars Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYCRAOAHAD
Specialty Pharmacy & Biologics Distribution

Keywords

  • GMP pharmaceutical manufacturing
  • Medicinal cannabis manufacturing
  • Investigational medicines distribution
  • Contract drug manufacturing
  • Consumer health supplements

Where Bioxyne is headquartered

Location

Headquarters

HQ city
Sydney
HQ country
Australia
HQ region
Oceania

Offices5 records

Markets served

Bioxyne business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Contract Pharmaceutical Manufacturing (GMP): Contract drug manufacturing services for clients including licensed clinics, pharmacies, wholesale distributors, cultivators, active pharmaceutical ingredient manufacturers, and pharmaceutical brand sponsors. Services include wholesale and distribution of medicinal cannabis, MDMA, and psilocybin products.
  2. Medicinal Cannabis Supply Agreements: Supply deals for medicinal cannabis products including the AU$50 million two-year supply agreement with ADREXpharma for the German market.
  3. Own-Brand Products (Dr Watson, PCC): Direct-to-consumer and retail distribution of own-brand prescription medicines and health products including Dr Watson CBD products, NADs, and food grade mushrooms.
  4. Wholesale Distribution Services: Wholesale distribution services for medicinal cannabis and controlled substances in Australia, Europe, UK, Japan, and USA through BLS Wholesalers and Breathe Life Sciences.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels5 records

Bioxyne product offering

Product offering

Core offering

Bioxyne, through its BLS Pharma and Breathe Life Sciences subsidiaries, is a contract drug manufacturer, sponsor, importer, exporter, and wholesale distributor of investigational medicines including medicinal cannabis, MDMA, and psilocybin products. It also produces and distributes own-brand consumer health products (Dr Watson, PCC) such as CBD, nootropics, functional mushrooms, NADs, and skincare via direct e-commerce and Amazon.

Product overview

BLS Pharma/Bioxyne operates a multi-brand pharmaceutical and life sciences platform consisting of the BLS (Breathe Life Sciences) manufacturing and wholesale subsidiary, Dr Watson® direct-to-consumer brand, and BLS Wholesalers. The core BLS subsidiary provides GMP-certified contract pharmaceutical manufacturing for cannabis, MDMA, and psilocybin products across Australia, Europe, and the UK. The Dr Watson® brand serves consumers with CBD supplements, nootropics, functional mushrooms, and skincare, while the PCC® brand represents legacy consumer health products. The group offers end-to-end services including R&D, manufacturing, quality control, import/export, and international distribution of investigational medicines and consumer health products.

Differentiator

Problem solved

Functional benefit

Brands

  • Dr Watson: Internationally trademarked direct-to-consumer brand featuring supplements, nootropics, functional mushrooms, and skincare. Approved by Amazon for CBD products. Operates in UK, EU, Japan, and USA.
  • BLS Wholesalers

Products and services

  • GMP Contract Pharmaceutical Manufacturing Contract drug manufacturing, sponsor, import, export, and wholesale distribution services for investigational and psychotropic medicines (cannabis, MDMA, psilocybin) delivered under TGA GMP licence for licensed clinics, pharmacies, wholesale distributors, cultivators, API manufacturers, and pharmaceutical brand sponsors.
  • GMP Psilocybin Capsules GMP-manufactured psilocybin capsules commercialised for the Australian market for investigational treatment of mental health disorders.
  • BLS Wholesalers Distribution Services Licensed wholesale distribution of Schedule 3, 4, and 8 medicines (medicinal cannabis and controlled substances) to pharmacies, manufacturers, and patients nationwide in Australia.
  • Dr Watson Consumer Health Brand Internationally trademarked direct-to-consumer brand featuring CBD products, NADs, functional mushrooms, nootropics, and skincare, distributed via direct e-commerce and Amazon in UK, EU, Japan, USA, and Australasia.

Quantifiable outcome

  • Scaled from $8M annual turnover to $8M monthly revenue
  • +2 more outcomes

Companies that use Bioxyne

Customer profile

Named customers3 records

Segments6 records

Ideal customer profiles5 records

Bioxyne technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Bioxyne partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • ADREXpharma GmbHcoreChannel Partner/ Reseller/ Distributor · 1 May 2026AU$50 million exclusive medicinal cannabis supply agreement with German pharmaceutical company ADREXpharma. Two-year contract facilitating Bioxyne's entry into the German medicinal cannabis market, with AU$25 million minimum guaranteed in first year. Deal significantly boosts European revenue visibility.
  • Aurora Cannabis Inc.coreStrategic or Co-development Partner · 1 April 2026Manufacturing agreement with global cannabis leader Aurora Cannabis Inc. covering GMP-certified medicinal cannabis oils for Australian market with first deliveries completed. Expansion planned into GMP-manufactured cannabis vapes for Australia, UK, and Germany. Deal provides third-party validation of Bioxyne's GMP manufacturing capabilities and entry into Aurora's global supply chain. Products include over 5,000 sublingual oil products and 20,000 vape units.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Bioxyne competitors and assessment

Company assessment

Broad incumbents

  • Aurora Cannabis Inc. NASDAQ/TSX-listed large global cannabis operator. Functions both as a Bioxyne customer (manufacturing agreement) and a broader incumbent shaping the global medicinal cannabis supply chain that Bioxyne contracts into.

Direct peers

  • MediPharm Labs Corp: TSX-listed (LABS) pure-play cannabis contract manufacturer with GMP-certified facilities. Highly analogous business model to BLS - contract GMP manufacturing and wholesale of cannabinoid APIs/products - making it one of the closest comparable contract manufacturers globally.
  • Cann Group Limited: ASX-listed Australian medicinal cannabis cultivator and manufacturer with TGA GMP-licensed facilities. Closest direct Australian comparison: same regulatory licensing environment, same customer base of clinics/pharmacies, overlapping Schedule 4/8 medicine focus.
  • Clever Leaves Holdings Inc. NASDAQ-listed (CLVR) Colombian-based GMP-certified cannabis cultivator and B2B manufacturer. Comparable contract-manufacturing and white-label distribution model serving international cannabis brands, similar to BLS's relationship with Aurora Cannabis.
  • Althea Group Holdings: ASX-listed (AGH) Australian medicinal cannabis company covering cultivation, manufacturing, wholesale distribution, and education to clinicians. Operates in the same TGA-licensed ecosystem and targets identical pharmacy/clinic customers.
  • Vitura Health Limited: ASX-listed (VIT, formerly Cronos Australia) Australian medicinal cannabis distribution and consumer health company. Direct peer operating in identical pharmacy/clinic distribution channels and competing for the same prescriber relationships across Australia.
  • Mind Medicine (MindMed) Inc. NASDAQ/NEO-listed (MNMD) psychedelic medicine developer focused on MDMA, LSD and psilocybin for mental health. Direct peer to Bioxyne's GMP MDMA/psilocybin manufacturing capability on the supply side of the same psychedelic ecosystem.
  • Bod Science Limited: ASX-listed (BOD) Australian medicinal cannabis and CBD consumer health company. Direct competitor in Australian pharmacy/clinic distribution and overlapping D2C CBD product lines with Bioxyne's Dr Watson brand.
  • Compass Pathways plc: NASDAQ-listed (CMPS) developer of psilocybin therapy for treatment-resistant depression. A direct peer in the same psychedelic medicine category Bioxyne manufactures for, sharing the mental-health indication focus and regulatory pathway timeline.

Regional players

  • Oxford Cannabinoid Technologies Holdings plc: LSE-listed (OCTP) UK-based cannabinoid drug development company. Operates in the same UK medicinal cannabis regulation environment as Bioxyne's Breathe Life Sciences UK entity and pursues overlapping novel cannabinoid therapeutics for pain indications.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Bioxyne social profiles

Digital presence

Bioxyne compliance and trust

Trust signal

Compliance5 records

Bioxyne financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bioxyne leadership team

Management profile

Number of profiles

Profiles1 record

Bioxyne subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Bioxyne funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bioxyne M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioxyne

What does Bioxyne do?

Bioxyne, through its BLS Pharma and Breathe Life Sciences subsidiaries, is a contract drug manufacturer, sponsor, importer, exporter, and wholesale distributor of investigational medicines including medicinal cannabis, MDMA, and psilocybin products. It also produces and distributes own-brand consumer health products (Dr Watson, PCC) such as CBD, nootropics, functional mushrooms, NADs, and skincare via direct e-commerce and Amazon.

Is Bioxyne a public or private company?

Bioxyne is a public company. It is classified as public and is currently operating.

When was Bioxyne founded?

Bioxyne was founded in 2010. It employs 51 to 100 people.

Where is Bioxyne based?

Bioxyne is headquartered in Sydney, Australia, in the Oceania region.

How does Bioxyne make money?

Four revenue lines are on record. Contract Pharmaceutical Manufacturing (GMP) is the primary driver. The others are medicinal Cannabis Supply Agreements, own-Brand Products (Dr Watson, PCC) and wholesale Distribution Services.

Who are Bioxyne's main competitors?

Aurora Cannabis Inc. is listed as a broad incumbent. Direct peers are MediPharm Labs Corp, Cann Group Limited, Clever Leaves Holdings Inc., Althea Group Holdings, Vitura Health Limited, Mind Medicine (MindMed) Inc., Bod Science Limited and Compass Pathways plc. Oxford Cannabinoid Technologies Holdings plc is listed as a regional player.

Does Bioxyne have an API?

No public API is recorded for Bioxyne.

What industry is Bioxyne in?

Bioxyne's product category is Contract Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGAGAL, GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification), with a secondary code of HLAIAJAH, Biologics & Biosimilars Distributors. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals